Literature DB >> 26977877

Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.

G Aaron Hobbs1, Alfred Wittinghofer2, Channing J Der3.   

Abstract

Two recent studies evaluated a small molecule that specifically binds to and inactivates the KRAS G12C mutant. The new findings argue that the perception that mutant KRAS is persistently frozen in its active GTP-bound form may not be accurate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26977877     DOI： 10.1016/j.ccell.2016.02.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  14 in total

Review 1.  The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance.

Authors:  Douglas E Biancur; Alec C Kimmelman
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-04-24       Impact factor: 10.680

2.  Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Andrew L Feldman
Journal:  Small GTPases       Date:  2017-01-06

3.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

4.  Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.

Authors:  Vincent L Cannataro; Stephen G Gaffney; Carly Stender; Zi-Ming Zhao; Mark Philips; Andrew E Greenstein; Jeffrey P Townsend
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

5.  Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.

Authors:  Shunsuke Kitajima; Hajime Asahina; Ting Chen; Sujuan Guo; Laura Gutierrez Quiceno; Jillian D Cavanaugh; Ashley A Merlino; Shoichiro Tange; Hideki Terai; Jong Wook Kim; Xiaoen Wang; Shan Zhou; Man Xu; Stephen Wang; Zehua Zhu; Tran C Thai; Chiaki Takahashi; Yujin Wang; Richard Neve; Susanna Stinson; Pablo Tamayo; Hideo Watanabe; Paul T Kirschmeier; Kwok-Kin Wong; David A Barbie
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

6.  Pulmonary Inflammation and KRAS Mutation in Lung Cancer.

Authors:  Phouthone Keohavong; Y Peter Di
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  SP3-FAIMS Chemoproteomics for High-Coverage Profiling of the Human Cysteinome*.

Authors:  Tianyang Yan; Heta S Desai; Lisa M Boatner; Stephanie L Yen; Jian Cao; Maria F Palafox; Yasaman Jami-Alahmadi; Keriann M Backus
Journal:  Chembiochem       Date:  2021-02-18       Impact factor: 3.164

8.  Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange.

Authors:  Sandrine Guillard; Paulina Kolasinska-Zwierz; Judit Debreczeni; Jason Breed; Jing Zhang; Nicolas Bery; Rose Marwood; Jon Tart; Ross Overman; Pawel Stocki; Bina Mistry; Christopher Phillips; Terence Rabbitts; Ronald Jackson; Ralph Minter
Journal:  Nat Commun       Date:  2017-07-14       Impact factor: 14.919

Review 9.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

10.  Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.

Authors:  Anuj Khandelwal; Caitlin N Kent; Maurie Balch; Shuxia Peng; Sanket J Mishra; Junpeng Deng; Victor W Day; Weiya Liu; Chitra Subramanian; Mark Cohen; Jeffery M Holzbeierlein; Robert Matts; Brian S J Blagg
Journal:  Nat Commun       Date:  2018-01-30       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.